Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116)
Rosen, E. Silverman, I. M. Fontana, E. Lee, E. K. Spigel, D. R. Hojgaard, M. Lheureux, S. Mettu, N. B. Carneiro, B. A. Carter, Louise
Rosen, E.
Silverman, I. M.
Fontana, E.
Lee, E. K.
Spigel, D. R.
Hojgaard, M.
Lheureux, S.
Mettu, N. B.
Carneiro, B. A.
Carter, Louise
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Rosen E, Silverman IM, Fontana E, Lee EK, Spigel DR, Hojgaard M, et al. Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300975.